Back

Tafamidis for the treatment of transthyretin cardiac amyloidosis (ATTR-CM) - Real-world data from a tertiary center.

1 September 2024 (17:24 - 17:36)
Organised by: Logo
Congress Presentation Part of: Advances in amyloidosis Pharmacotherapy ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Rita Carvalho

Western Lisbon Hospital Centre, EPE, Lisbon (Portugal)

4 More presentations in this session

Presentation thumbnail
Patient journey from the appearance of red flags to the diagnosis of transthyretin cardiac amyloidosis (ATTR-CM) in Japan: a nationwide retrospective study using a medical claims database
Doctor H. Abe (Tokyo, JP)
Abstract Slides Video
Presentation thumbnail
Long-term all-cause and cardiovascular-related mortality in patients with ATTR-CM treated with continuous tafamidis vs placebo to tafamidis by NAC stage at baseline
Professor M. Fontana (London, GB)
Abstract Slides Video
Presentation thumbnail
Long-term effects of patisiran on survival and cardiac parameters in patients with transthyretin-mediated cardiac amyloidosis: post hoc analysis of APOLLO-B and cardiac subpopulation of APOLLO OLE
Professor O. Lairez (Toulouse, FR)
Abstract Slides Video
Presentation thumbnail
Long-term safety and efficacy of antibody ALXN2220 for depletion of cardiac amyloid transthyretin: results of treatment beyond 12 months in the open-label extension of study NI006-101
Professor P. Van Der Meer (Groningen, NL)
Abstract Slides Video

Access the full session

Session thumbnail
Advances in amyloidosis
Video

The Event

Event poster

ESC Congress 2024

1 September 2024 17:24 CET
You may be interested in
thumbnail
Congress Presentation
Tafamidis to treat patients with transthyretin cardiac amyloidosis (ATTR-CM): real-world data from a tertiary centre
thumbnail
Congress Presentation
Tafamidis for the treatment of transthyretin cardiac amyloidosis (ATTR-CM) - Real-world data from a tertiary center.
thumbnail
Congress Presentation
Impact of Tafamidis on clinical outcomes in real-world patients with ATTR-CM

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources